Apotex Holdings Inc. completes sale of Accucaps Industries to Catalent Pharma Solutions

On February 16, 2017, Catalent Pharma Solutions Ltd. announced the completion of its purchase of all of the shares of Accucaps Industries Ltd. from Apotex Holdings Inc. for an undisclosed price. 

Accucaps is a developer and manufacturer of over-the-counter pharmaceutical softgels and operates two state-of-the art softgel development, manufacturing and packaging facilities in Windsor and Strathroy, Ont. The acquisition complements and enhances Catalent’s global network of 11 softgel technology facilities. 

Apotex Holdings Inc. was represented by Torkin Manes LLP, with a team led by Jeffrey Cohen and including Sammy Redlick and Adrian Myers. Davies Ward Phillips & Vineberg LLP provided tax counsel to Apotex, with a team led by Elie Roth and including Andrew Ellis. 

Catalent was represented by Fried, Frank, Harris, Shriver & Jacobson LLP, with a team led by corporate partners Steven Epstein and Matthew Soran and including tax partner Michael Alter and corporate special counsel Brian Blitz and by Blake, Cassels & Graydon LLP in Canada with a  team led by Cheryl Satin, and including Geoff Belsher, Michael Elder, Kathryn Houlden (corporate /M&A), Julie Soloway, and including Kate McNeece and Brian Facey (competition/anti-trust), Jeffrey Shafer (tax), Laura Weinrib (health regulatory), Anna Abbott, Holly Reid (labour & employment), Lindsay McLeod (pension & benefits), Beth Earon, Patrick Gordon (real estate), Jonathan Kahn (environmental) and David Feldman (IT).

Lexpert Copyrights © Thomson Reuters Canada Limited